Table of Contents
Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Testicular Cancer in 20 Major Markets
Testicular Cancer is a relatively rare cancer; although it is the most commonly diagnosed cancer in males aged 20-34. There are two main types of testicular cancer; seminomas and non seminomas, which develop from germ cells in the testicles. The standard treatment procedure involves the complete removal of the testis with the tumour.
This report provides the current incidence population for Testicular Cancer across 20 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Australia, Canada, Mexico, Turkey, Switzerland, Norway, Denmark, South Africa, Saudi Arabia, Argentina and Russia) split by male 5-year age cohort. Along with the current incidence, the report provides an overview of the stages, locations and histopathology of Testicular Cancer tumours. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms of Testicular Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Testicular Cancer include:
-Presence of lump in one testis
-Pain (lower back, scrotum or lower abdomen)
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
-Able to quantify patient populations in global Testicular Cancer’s market to target the development of future products, pricing strategies and launch plans.
-Gain further insight into the incidence of the subdivided types of Testicular Cancer and identify patient segments with high potential.
-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
-Provide a level of understanding on the impact from specific co-morbid conditions on Testicular Cancer’s incident population.
-Examination of various elevated serum levels present in Testicular Cancer patients.
-Identify sub-populations within Testicular Cancer which require treatment.
-Gain an understanding of the specific markets that have the largest number of Testicular Cancer patients.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...
Complete report $9,800. DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...
MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts Summary Companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows ...